Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Oncopeptides. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Oncopeptides's earnings available for a low price, and how does
this compare to other companies in the same industry?
Oncopeptides's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Oncopeptides is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Oncopeptides's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Jakob Lindberg, Med. Lic has been the Chief Executive officer of Oncopeptides AB since October 2011. Dr. Lindberg is a Venture Partner at Investor Growth Capital Europe. He is the Owner of Cellectricon AB. He was a Vice President of Investor Growth Capital AB. Dr. Lindberg joined Investor Growth Capital in 2005. He focused on investments in life sciences and healthcare sector. Dr. Lindberg was a Co-Founder at Cellectricon AB and served as its Chief Executive Officer from 2000 to 2004. He has worked at McKinsey & Co. as an active member of healthcare practice. He served as a Director at Atlas Antibodies AB, Åmic AB and Heartscape Technologies, Inc. He serves as a Director of NeuroNova AB and Affibody Medical AB (publ). Dr. Lindberg serves as Director of Affibody Holding AB (also known as, Affibody AB). He served as an Independent Director of Alligator Bioscience AB (publ) since 2013 until May 2, 2017. He served as a Director of Cellectricon AB and SciBase AB. He served as a Director of Dipylon Medical AB. He served as Non-Executive Director of Newron Pharmaceuticals S.p.A. since December 17, 2012. He served as a Director of Sidec Technologies AB. He holds a Med. Lic in Molecular Immunology and a MSc in pre-clinical medicine from the Karolinska Institutet. Dr. Lindberg is a licensed Swedish physician with an M.D. from the Karolinska Institute and a B.A. in Finance and Administration from Stockholm University.
Jakob's compensation has increased whilst company is loss making.
Jakob's remuneration is about average for companies of similar size in Sweden.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Oncopeptides management team is about average.
Chief Executive Officer
Chief Financial Officer
Executive VP of Clinical Strategy
Head of Investor Relations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Oncopeptides board of directors is about average.
Does Market Volatility Impact Oncopeptides AB (publ)'s (STO:ONCO) Share Price?
If you're interested in Oncopeptides AB (publ) (STO:ONCO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … The first thing to understand about beta is that the beta of the overall market is one.
Investors Who Bought Oncopeptides (STO:ONCO) Shares A Year Ago Are Now Up 69%
To wit, the Oncopeptides AB (publ) (STO:ONCO) share price is 69% higher than it was a year ago, much better than the market return of around 7.2% (not including dividends) in the same period. … With zero revenue generated over twelve months, we don't think that Oncopeptides has proved its business plan yet. … It's a testament to the popularity of the business plan that the share price gained 69% in the last year, despite the weak balance sheet.
Oncopeptides AB (publ) (STO:ONCO) Insiders Have Been Selling
So before you buy or sell Oncopeptides AB (publ) (STO:ONCO), you may well want to know whether insiders have been buying or selling. … We generally tread carefully if insiders have been selling on market, even if they sold slightly above the current price. … All up, insiders sold more shares in Oncopeptides than they bought, over the last year
Could The Oncopeptides AB (publ) (STO:ONCO) Ownership Structure Tell Us Something Useful?
Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Oncopeptides is not a large company by global standards.
Loss-Making Oncopeptides AB (publ) (STO:ONCO) Expected To Breakeven
The kr5.7b market-cap posted a loss in its most recent financial year of -kr249.5m and a latest trailing-twelve-month loss of -kr376.7m leading to an even wider gap between loss and breakeven? … The most pressing concern for investors is ONCO’s path to profitability – when will it breakeven. … Check out our latest analysis for Oncopeptides
Should You Be Worried About Insider Transactions At Oncopeptides AB (publ) (STO:ONCO)?
So shareholders might well want to know whether insiders have been buying or selling shares in Oncopeptides AB (publ) (STO:ONCO). … But insiders sold 19.10k shares worth kr3.1m. … All up, insiders sold more shares in Oncopeptides than they bought, over the last year.
Can We See Significant Institutional Ownership On The Oncopeptides AB (publ) (STO:ONCO) Share Register?
The big shareholder groups in Oncopeptides AB (publ) (STO:ONCO) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that have been privatized tend to have low insider ownership.
Who Are The Top Investors In Oncopeptides AB (publ) (STO:ONCO)?
In this analysis, my focus will be on developing a perspective on Oncopeptides AB (publ)’s (STO:ONCO) latest ownership structure, a less discussed, but important factor. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine ONCO's ownership structure in more detail.
Oncopeptides AB (publ), a clinical development pharmaceutical company, develops anti-cancer drugs. It develops Ygalo, a cytotoxic therapy that is in late-stage development use for the treatment of multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.